OPTIMAL ADMINISTRATION DURATION OF URACIL-TEGAFUR ON ADJUVANT CHEMOTHERAPY FOR COMPLETELY RESECTED STAGE I LUNG ADENOCARCINOMA: RETROSPECTIVE ANALYSIS FROM JLCRG PHASE III STUDY

被引：0
|
作者：
Tsuboi, M. [1 ]
Hamada, C. [2 ]
机构：
[1] Kanagawa Canc Ctr, Yokohama, Kanagawa 2410815, Japan
[2] Tokyo Univ Sci, Fac Engn, Tokyo 162, Japan
[3] Japan Lung Canc Res Grp, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：154 / 154
页数：1
相关论文
共 50 条
  • [31] Oral adjuvant chemotherapy using uracil-tegafur (UFT) with leucovorin (LV) after resection of colorectal cancer liver metastases: Long-term survival results of the phase III UFT/LV study
    Hasegawa, Kiyoshi
    Saiura, Akio
    Takayama, Tadatoshi
    Miyagawa, Shinichi
    Yamamoto, Junji
    Bandai, Yasutsugu
    Teruya, Masanori
    Yoshimi, Fuyo
    Kawasaki, Seiji
    Koyama, Hiroto
    Oba, Masaru
    Takahashi, Michiro
    Yamashita, Suguru
    Mizunuma, Nobuyuki
    Matsuyama, Yutaka
    Watanabe, Toshiaki
    Makuuchi, Masatoshi
    Kokudo, Norihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [32] Phase III Trial of Treatment Duration of Oral Uracil and Tegafur/Leucovorin Adjuvant Chemotherapy for Patients (pts) With Stage IIb/III Colon Cancer - an Interim Safety and Feasibility Report, JFMC33-0502
    Sasaki, K.
    Sadahiro, S.
    Tsuchiya, H.
    Kondo, K.
    Katsumata, K.
    Nishimura, G.
    Kakeji, Y.
    Satou, S.
    Baba, S.
    Kodaira, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S413 - S413
  • [33] A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non-small cell lung cancer (JCOG 0707)
    Kunitoh, Hideo
    Tsuboi, Masahiro
    Wakabayashi, Masashi
    Okada, Morihito
    Suzuki, Kenji
    Watanabe, Shun-ichi
    Asamura, Hisao
    JTCVS OPEN, 2020, 4 : 90 - 102
  • [34] Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial
    Tsuchiya, Takashi
    Sadahiro, Sotaro
    Sasaki, Kazuaki
    Kondo, Ken
    Katsumata, Kenji
    Nishimura, Genichi
    Kakeji, Yoshihiro
    Baba, Hideo
    Morita, Takayuki
    Koda, Keiji
    Sato, Seiji
    Matsuoka, Junji
    Yamaguchi, Yoshiyuki
    Usuki, Hisashi
    Hamada, Chikuma
    Kodaira, Susumu
    Saji, Shigetoyo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (06) : 1253 - 1261
  • [35] Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer
    Makoto Sonobe
    Ken-ichi Okubo
    Satoshi Teramukai
    Kazuhiro Yanagihara
    Masaaki Sato
    Toshihiko Sato
    Fengshi Chen
    Kiyoshi Sato
    Takuji Fujinaga
    Tsuyoshi Shoji
    Mitsugu Omasa
    Hiroaki Sakai
    Ryo Miyahara
    Toru Bando
    Hiroshi Date
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1199 - 1206
  • [36] Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer
    Sonobe, Makoto
    Okubo, Ken-ichi
    Teramukai, Satoshi
    Yanagihara, Kazuhiro
    Sato, Masaaki
    Sato, Toshihiko
    Chen, Fengshi
    Sato, Kiyoshi
    Fujinaga, Takuji
    Shoji, Tsuyoshi
    Omasa, Mitsugu
    Sakai, Hiroaki
    Miyahara, Ryo
    Bando, Toru
    Date, Hiroshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (06) : 1199 - 1206
  • [37] A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv, Chao
    An, Chao
    Feng, Qin
    Ma, Yuanyuan
    Li, Shaolei
    Wang, Jia
    Zhang, Jianzhi
    Wang, Xing
    Yan, Shi
    Fang, Jian
    Wang, Yinxiang
    Tan, Fenlai
    Yang, Yue
    CLINICAL LUNG CANCER, 2015, 16 (06) : E173 - E181
  • [38] A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJS']JSG) - the 4th study
    Nakagawa, M
    Tanaka, F
    Tsubota, N
    Ohta, M
    Takao, M
    Wada, H
    ANNALS OF ONCOLOGY, 2005, 16 (01) : 75 - 80
  • [39] A Phase II Study of Adjuvant Chemotherapy with Tegafur-Uracil for Vessel Invasion Positive Stage IA Non-Small Cell Lung Cancer (LOGIK0602)
    Tsuchiya, T.
    Nagayasu, T.
    Kamohara, R.
    Muraoka, M.
    Saeki, S.
    Ichinose, Y.
    Suzuki, M.
    Inada, K.
    Tokunaga, S.
    Hayashi, T.
    Urabe, S.
    Koga, T.
    Akamine, S.
    Sugio, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S652 - S652
  • [40] Randomized Phase Ill Trial of Adjuvant Chemotherapy With Gemcitabine Compared With Oral Tegafur-uracil (UFT) in Resected, Stage IB-IIIa Non-small Cell Lung Cancer (WJTOG 0101)
    Mitsudomi, T.
    Tada, H.
    Ichinose, Y.
    Yokoi, K.
    Katakami, N.
    Oda, M.
    Negoro, S.
    Chiba, Y.
    Nakagawa, K.
    Nakanishi, Y.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S594 - S594
12345